A Phase I Study of Nivolumab in Combination With Escalating Doses of Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

A Phase I Study of Nivolumab in Combination With Escalating Doses of Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 May 2017

At a glance

  • Drugs Nivolumab (Primary) ; Plinabulin (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Sep 2016 According to a BeyondSpring Pharmaceuticals media release, the first patient in the trial was enrolled on September 7, 2016 at the University of California San Diego Moores Cancer Center, and has completed the first cycle of the combination treatment.
    • 27 Sep 2016 Status changed from not yet recruiting to recruiting, according to a BeyondSpring Pharmaceuticals media release.
    • 14 Jul 2016 According to BeyondSpring Pharmaceuticals media release, company announced that on June 20, 2016, the U.S. FDA notified Dr. Lyudmila Bazhenova at the UC San Diego Moores Cancer Center that this trial may proceed with enrolling patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top